PDCD1 and soft tissue sarcoma: A multicenter, open-label phase 2 trial included the treatment of soft tissue sarcoma with nivolumab offered no evidence of clinical activity in soft tissue sarcoma containing 2 patients with MFS.[5] Nonetheless, another phase 2 trial informed 7 (18%) of 40 patients with soft-tissue sarcoma showed an objective response to pembrolizumab.[6] As a subset of soft tissue sarcoma, a few cases of MFS treated with PD-1 blockades are reported.